Practice Tip: Act Sooner vs Later on Employee Termination
“Once the practice owner/manager has identified an employee who is not improving despite the setting of expectations and related conversations, they should remove the employee sooner vs. later,” writes Patricia Fulmer, OD, in her latest “Staffing” column. The reasons: The negativity, insubordination, and/or poor performance of an employee can be both contagious and lead to decreased team morale, she adds. To see the ramifications of this, read here. 

Atia Vision Receives U.S. Food and Drug Administration’s Investigational Device Exemption Approval for Feasibility Study of Intraocular Lens
Atia Vision received the U.S. Food and Drug Administration’s Investigational Device Exemption to start a traditional feasibility clinical study of its OmniVu Lens System. The system is comprised of two distinct components: a fluid-filled shape-changing base that provides focusing capability, or zoom function, and a front optic that docks into the base to provide the intraocular lens’ optical power, according to a press release.

Bausch + Lomb Launches Preservative Free Redness-Reliever Eye Drops
Bausch + Lomb has made available Lumify Preservative Free redness reliever over-the-counter eye drops whose mechanism of action is low-dose brimonidine tartrate 0.025%. The drops are now available in single-use vials at most retailers nationwide, including Walmart, Target, CVS, Walgreens, Rite Aid and Amazon, according to a press release.

Bostonsight Announces Members to Board of Directors
BostonSight elected Mr. Michael (Mike) Nash and Mr. Ramam Atmakuri to its Board of Directors. Mr. Nash, now a Customer Experience and Technology consultant and mentor, was most recently senior vice president and chief customer xperience officer at HP Inc. Mr. Atmakuri is the executive vice chair emeritus at LV Prasad Eye Institute in India, and served as its executive vice chair, managing nonclinical operations across the Institute’s network.

CooperVision Relaunches Science and Technology Awards Program
CooperVision relaunched its Science and Technology Awards Program. The program’s focus this year is on myopia, with a call for seedling award proposals that support innovative early stage research in topic areas, such as new approaches to understanding the underlying mechanisms of myopia onset, progression, and control. The awards are available to postdoctoral fellows, and young and established investigators. Each award provides up to $100,000 in funding over a 1-year period. For more information and to review submission guidelines, visit https://coopervision.com/our-company/science-and-technology-awards.

Selagine Obtains U.S. Food and Drug Administration Investigational New Drug Clearance for Dry Eye Disease Treatment
Selagine, Inc., a spin-out company from the University of Illinois Chicago obtained the U.S. Food and Drug Administration’s Investigational New Drug clearance for its immunoglobulin drops (GRF312 ophthalmic solution) for the treatment of patients who have dry eye disease. The drops are anti-inflammatory and immunomodulatory and generated from pooled human plasma from thousands of healthy donors, according to a press release. For more information, visit www.selagine.com